Safety and effect of a new artificial saliva containing Zingiber officinale and Cuminum cyminum on stimulating saliva secretion: In vitro, in vivo and preliminary clinical study
{"title":"Safety and effect of a new artificial saliva containing Zingiber officinale and Cuminum cyminum on stimulating saliva secretion: In vitro, in vivo and preliminary clinical study","authors":"Supamas Napavichayanun , Sutima Luangdilok , Rungnapha Yamdech , Pornanong Aramwit","doi":"10.1016/j.eujim.2024.102396","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Xerostomia is a symptom that affects quality of life and may lead to malnutrition. While artificial saliva is used as a lubricant for the oral cavity, it rarely stimulates saliva secretion. The objective of this study was to develop a herbal artificial saliva (HAS) that could stimulate saliva secretion and be safe for human consumption.</p></div><div><h3>Methods</h3><p>Three HAS formulations were prepared with 0.3 % <em>Cuminum cyminum</em> extract and 0.05 %, 0.10 %, and 0.15 % <em>Zingiber officinale</em> extract (HAS0.05, HAS 0.10, and HAS0.15, respectively). <em>In vivo</em> skin and oral mucosal irritation tests were used to evaluate the safety of HAS0.15. Additionally, the preliminary efficacy and safety of the three HAS formulations were investigated in 21 healthy volunteers. The sample was sprayed into the oral cavity under the left and right sides of the tongue. Thirty minutes after spraying, the amount of saliva was assessed using a visual analogue scale and a Schirmer strip. In addition, dry mouth symptoms, the saliva pH, and adverse reactions were assessed before and after testing.</p></div><div><h3>Results</h3><p>HAS0.15 caused minimal skin irritation and did not alter the epithelium or other structures of the oral mucosa. The saliva quantity after using HAS0.10 and HAS0.15 was significantly higher than prior to testing (<em>p</em> < 0.05). None of the formulations induced mucositis or adverse reactions.</p></div><div><h3>Conclusion</h3><p>This study was successful in the development of a new HAS that stimulated saliva secretion and was safe for humans. However, this study is preliminary: Further clinical investigation in patients with hyposalivation will confirm the efficacy of this novel HAS. This novel HAS may be an alternative treatment for the elderly and patients with hyposalivation.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"70 ","pages":"Article 102396"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382024000659","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Xerostomia is a symptom that affects quality of life and may lead to malnutrition. While artificial saliva is used as a lubricant for the oral cavity, it rarely stimulates saliva secretion. The objective of this study was to develop a herbal artificial saliva (HAS) that could stimulate saliva secretion and be safe for human consumption.
Methods
Three HAS formulations were prepared with 0.3 % Cuminum cyminum extract and 0.05 %, 0.10 %, and 0.15 % Zingiber officinale extract (HAS0.05, HAS 0.10, and HAS0.15, respectively). In vivo skin and oral mucosal irritation tests were used to evaluate the safety of HAS0.15. Additionally, the preliminary efficacy and safety of the three HAS formulations were investigated in 21 healthy volunteers. The sample was sprayed into the oral cavity under the left and right sides of the tongue. Thirty minutes after spraying, the amount of saliva was assessed using a visual analogue scale and a Schirmer strip. In addition, dry mouth symptoms, the saliva pH, and adverse reactions were assessed before and after testing.
Results
HAS0.15 caused minimal skin irritation and did not alter the epithelium or other structures of the oral mucosa. The saliva quantity after using HAS0.10 and HAS0.15 was significantly higher than prior to testing (p < 0.05). None of the formulations induced mucositis or adverse reactions.
Conclusion
This study was successful in the development of a new HAS that stimulated saliva secretion and was safe for humans. However, this study is preliminary: Further clinical investigation in patients with hyposalivation will confirm the efficacy of this novel HAS. This novel HAS may be an alternative treatment for the elderly and patients with hyposalivation.
期刊介绍:
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.